Owings Mills, Maryland, United States
Owings Mills, Maryland, United States

Time filter

Source Type

News Article | December 5, 2016
Site: www.newsmaker.com.au

Obese people are increasing globally, which is leading to many diseases such as heart diseases, hypertension, cancer, high blood pressure and diabetes. Treatment of such diseases is quite expensive and government has to bear the costs to improve the healthcare infrastructure. Obesity is a very serious medical condition in which body has excess fat deposition. Increase consumption of unhygienic fatty foods or intake of too many calories and genetic inheritance are the main causes of obesity. With the rising population, obese people have increased not only of the developed nations but also of the developing nations too. According to World Health Organization, 1.6 billion adults are overweight worldwide and another 400 million are obese. They also say that 20 million children below 5 years of age are overweight. Obesity reduces life expectancy, Technological advancement, increasing number of diseases, increasing personal disposable income, increase intake of high-calorie food and beverages due to urbanization, reduced physical activity, unhealthy lifestyle are the most important driving factors in obesity management market. There’s a sea change in the consumer’s habits, lifestyle and eating patterns. Companies are emphasizing more on digital advertising and social media to lure consumers for junk food consumption and try products which can be harmful for their health. United States has the most obese people followed by China. US has created and designed special ambulance just for obese people since normal ambulances cannot take the weight of obese people. The high cost of the obesity programme, increasing health awareness of food and beverages by consumers, post obesity programme or surgery harmful effects and complications are acting as a barrier for obesity management market. Obesity Management Market is broadly classified on the basisof the following segments – The obesity management market has grown substantially at a healthy CAGR due to increase per capita spending on diet food and beverages products, rising disposable income, strong desire among men and women to look fit and healthy. With rapid technological advancement and variety of options available in the market, obesity management market is expected to grow. North America represents the largest market for this product category. Asia Pacific will emerge as the fastest growing region in an obesity management market. The obesity management market is expected to register a double-digit CAGR for the forecast period. Depending on geographic regions, obesity management market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa. As of 2015, North America dominated the obesity management market in terms of market revenue. Asia is the fastest growing market. There’s a robust demand from Europe for obesity management market. Some of the key market players in obesity management market are Atkins Nutritional Inc, Nutrisystem Inc, Ediets.com, Medifast Inc, Herbal Life, Precor, Life Fitness, Cybex International, Star Trac, Technogym.


Cheskin L.J.,Johns Hopkins Weight Management Center | Sonzone C.M.,Medifast Inc. | Davis L.M.,Villanova University
Neurology: Clinical Practice | Year: 2012

Obesity and excess body fat contribute to both the risk for and progression of several prevalent neurologic conditions. While obesity treatment is not generally considered part of the job description of the neurologist, we summarize the evidence for this important relationship, and describe ways that being mindful of diet and lifestyle factors in the neurologic patient can yield dividends for patient outcomes. Copyright © by AAN Enterprises, Inc.


Davis L.M.,Medifast Inc | Coleman C.,Medifast Inc | Kiel J.,Medifast Inc | Rampolla J.,Medifast Inc | And 4 more authors.
Nutrition journal | Year: 2010

BACKGROUND: Obesity has reached epidemic proportions in the United States. It is implicated in the development of a variety of chronic disease states and is associated with increased levels of inflammation and oxidative stress. The objective of this study is to examine the effect of Medifast's meal replacement program (MD) on body weight, body composition, and biomarkers of inflammation and oxidative stress among obese individuals following a period of weight loss and weight maintenance compared to a an isocaloric, food-based diet (FB). METHODS: This 40-week randomized, controlled clinical trial included 90 obese adults with a body mass index (BMI) between 30 and 50 kg/m2, randomly assigned to one of two weight loss programs for 16 weeks and then followed for a 24-week period of weight maintenance. The dietary interventions consisted of Medifast's meal replacement program for weight loss and weight maintenance, or a self-selected, isocaloric, food-based meal plan. RESULTS: Weight loss at 16 weeks was significantly better in the Medifast group (MD) versus the food-based group (FB) (12.3% vs. 6.9%), and while significantly more weight was regained during weight maintenance on MD versus FB, overall greater weight loss was achieved on MD versus FB. Significantly more of the MD participants lost >or= 5% of their initial weight at week 16 (93% vs. 55%) and week 40 (62% vs. 30%). There was no difference in satiety observed between the two groups during the weight loss phase. Significant improvements in body composition were also observed in MD participants compared to FB at week 16 and week 40. At week 40, both groups experienced improvements in biochemical outcomes and other clinical indicators. CONCLUSIONS: Our data suggest that the meal replacement diet plan evaluated was an effective strategy for producing robust initial weight loss and for achieving improvements in a number of health-related parameters during weight maintenance, including inflammation and oxidative stress, two key factors more recently shown to underlie our most common chronic diseases. TRIAL REGISTRATION: ClinicalTrials.gov NCT01011491.


Coleman C.D.,Medifast Inc | Kiel J.R.,Medifast Inc | Mitola A.H.,Independent Consultant | Langford J.S.,Medifast Inc | And 2 more authors.
Nutrition Journal | Year: 2015

Abstract Background: Recent medical guidelines emphasize the importance of actively treating overweight and obesity with diet and lifestyle intervention to achieve ≥5 % weight loss in a 6-month period. Commercial programs offer one approach provided there is evidence of their efficacy and safety. This study was conducted to evaluate the effectiveness of the Medifast® 4 & 2 & 1 Plan™ on weight loss, body composition and cardiometabolic risk factors in overweight and obese adults. Methods: A systematic retrospective chart review of 310 overweight and obese clients following the Medifast 4 & 2 & 1 Plan at one of 21 Medifast Weight Control Centers® was conducted. Data were recorded electronically and key data points were independently verified. The primary endpoint was change from baseline body weight at 12 weeks. Within group paired t-tests were used to examine changes from baseline in a completers population. Differences between gender and age subgroups were examined using bivariate t-tests and mixed model regression analyses. Results: For the primary endpoint at 12 weeks, body weight among completers (n = 185) was reduced by a mean of 10.9 ± 5.6 kg (-10.1 %, p < 0.0001), and at 24 weeks (n = 81) mean weight was reduced by 16.0 ± 7.9 kg (-14.3 %). At 12 and 24 weeks, 85 % and 96 % of those remaining on the plan, respectively, had lost ≥5 % of their baseline body weight. Lean mass was preserved to within 5 % of baseline throughout the 24 weeks, and fat mass represented ≥80 % of the body weight lost from 12 weeks onward. Men, women, seniors (≥65 years), and non-seniors (<65 years) all had significant weight reductions with preservation of lean mass. Significant improvements in blood pressure, pulse and waist-to-hip ratio were observed. Mean weight regain among the subset who entered a formal maintenance phase was <2 % during an average follow-up of 34 weeks. The meal plan was well tolerated, and program adherence was >85 %. Conclusions: The 4 & 2 & 1 Plan used at Medifast Weight Control Centers was effective for weight loss, preservation of lean mass and improvement in cardiometabolic risk factors. The plan was generally well tolerated in a broad population of overweight and obese adults. #NCT02150837. © 2015 Coleman et al.


Recent medical guidelines emphasize the importance of actively treating overweight and obesity with diet and lifestyle intervention to achieve 5% weight loss in a 6-month period. Commercial programs offer one approach provided there is evidence of their efficacy and safety. This study was conducted to evaluate the effectiveness of the Medifast 4 & 2 & 1 Plan on weight loss, body composition and cardiometabolic risk factors in overweight and obese adults.A systematic retrospective chart review of 310 overweight and obese clients following the Medifast 4 & 2 & 1 Plan at one of 21 Medifast Weight Control Centers was conducted. Data were recorded electronically and key data points were independently verified. The primary endpoint was change from baseline body weight at 12 weeks. Within group paired t-tests were used to examine changes from baseline in a completers population. Differences between gender and age subgroups were examined using bivariate t-tests and mixed model regression analyses.For the primary endpoint at 12 weeks, body weight among completers (n = 185) was reduced by a mean of 10.9 5.6 kg (-10.1%, p < 0.0001), and at 24 weeks (n = 81) mean weight was reduced by 16.0 7.9 kg (-14.3%). At 12 and 24 weeks, 85% and 96% of those remaining on the plan, respectively, had lost 5% of their baseline body weight. Lean mass was preserved to within 5% of baseline throughout the 24 weeks, and fat mass represented 80% of the body weight lost from 12 weeks onward. Men, women, seniors ( 65 years), and non-seniors (<65 years) all had significant weight reductions with preservation of lean mass. Significant improvements in blood pressure, pulse and waist-to-hip ratio were observed. Mean weight regain among the subset who entered a formal maintenance phase was <2% during an average follow-up of 34 weeks. The meal plan was well tolerated, and program adherence was >85%.The 4 & 2 & 1 Plan used at Medifast Weight Control Centers was effective for weight loss, preservation of lean mass and improvement in cardiometabolic risk factors. The plan was generally well tolerated in a broad population of overweight and obese adults. #NCT02150837.


Obesity has reached epidemic proportions in the United States. It is implicated in the development of a variety of chronic disease states and is associated with increased levels of inflammation and oxidative stress. The objective of this study is to examine the effect of Medifasts meal replacement program (MD) on body weight, body composition, and biomarkers of inflammation and oxidative stress among obese individuals following a period of weight loss and weight maintenance compared to a an isocaloric, food-based diet (FB).This 40-week randomized, controlled clinical trial included 90 obese adults with a body mass index (BMI) between 30 and 50 kg/m2, randomly assigned to one of two weight loss programs for 16 weeks and then followed for a 24-week period of weight maintenance. The dietary interventions consisted of Medifasts meal replacement program for weight loss and weight maintenance, or a self-selected, isocaloric, food-based meal plan.Weight loss at 16 weeks was significantly better in the Medifast group (MD) versus the food-based group (FB) (12.3% vs. 6.9%), and while significantly more weight was regained during weight maintenance on MD versus FB, overall greater weight loss was achieved on MD versus FB. Significantly more of the MD participants lost >or= 5% of their initial weight at week 16 (93% vs. 55%) and week 40 (62% vs. 30%). There was no difference in satiety observed between the two groups during the weight loss phase. Significant improvements in body composition were also observed in MD participants compared to FB at week 16 and week 40. At week 40, both groups experienced improvements in biochemical outcomes and other clinical indicators.Our data suggest that the meal replacement diet plan evaluated was an effective strategy for producing robust initial weight loss and for achieving improvements in a number of health-related parameters during weight maintenance, including inflammation and oxidative stress, two key factors more recently shown to underlie our most common chronic diseases.ClinicalTrials.gov NCT01011491.

Loading Medifast Inc collaborators
Loading Medifast Inc collaborators